Overview
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Last reviewed: 12 January 2023
This guidance replaces the NICE medtech innovation briefing on LiverMultiScan for liver disease (MIB181).
Diagnostics guidance 50 has been migrated to HealthTech guidance 655.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.